The mechanism of action of peptide inhibitors on angiotensin I-converting enzyme (Al-converting enzyme) was studied in relation to the substrate requirements of the enzyme in vivo in the dog lung and in vitro in plasma. l-</-Asp-8-Ile-AI prepared by the solid-phase technique was compared with the known peptide inhibitors of Al-converting enzyme. BPP 5il (Pyr-Lys-Trp-Ala-Pro) and SQ 20881 (Pyr-Trp-Pro-Arg-Pro-Gln-IlePro-Pro) 125 I-l-d-Asp-8-Ile-AI was evaluated for susceptibility to cleavage by the Al-converting enzyme. In vitro and in vivo, l25 I-l-d-Asp-8-Ile-AI or BPP 5a in 50,000-fold molar excess produced only a slight delay in conversion of • The pressor effects of angiotensin I are due mainly to its rapid conversion to angiotensin II by a dipeptidylcarboxypeptidase in the pulmonary circulation (1-4). Previous studies from our laboratory (5) have demonstrated that angiotensin I (AI) analogues containing c/-amino acid substitutions near the C-terminus are not converted to angiotensin II (All) in plasma or the pulmonary circulation and do not block the conversion of native AI. Similarly, the C-terminal sequence of All is important for binding to receptor sites (6). All analogues containing He in position 8 are potent competitive antagonists of All (7). An AI analogue containing lie in position 8 might then interfere with the renin-angiotensin system by two mechanisms: (1) competing with AI for converting enzyme and (2) generating an All antagonist. In earlier pharmacologic studies (8, 9), the decapeptide 8-Ile-AI was found to be weakly antagonistic to both AI and All in a variety of smooth muscle preparations and in the intact rat. Addition of the converting enzyme inhibitor SQ 20881 (Pyr-TrpPro-Arg-Pro-Gln-Ile-Pro-Pro) diminished but did not abolish the antagonism of 8-Ile-AI for All in the rat pressor assay, suggesting that conversion of small amounts of 8-Ile-AI to 8-Ile-AII took place in this preparation (8). To further evaluate 8-Ilesubstituted AI for susceptibility to converting enzyme and ability to block the conversion of native AI, l-d-Asp-8-Ile-AI was synthesized and studied in vitro in plasma and in vivo in the pulmonary circulation of the intact dog. Comparisons with known peptide inhibitors of converting enzyme were made.
I-angiotension II (All); SQ 20881 blocked conversion completely. In vivo, l-d-Asp-8-Ile-AI or BPP 3a injected into the pulmonary circulation in 250-fold molar excess (250 nmole/kg) did not cause a diminution in the pressor response to AI administered 30 seconds later; SQ 20881 blocked the pressor response to AI for 60-90 minutes. l-rf-Asp-8-Ile-AI was a poor substrate for converting enzyme, since 125 I-l-c/-Asp-8-Ile-AI was riot converted to • The pressor effects of angiotensin I are due mainly to its rapid conversion to angiotensin II by a dipeptidylcarboxypeptidase in the pulmonary circulation (1-4). Previous studies from our laboratory (5) have demonstrated that angiotensin I (AI) analogues containing c/-amino acid substitutions near the C-terminus are not converted to angiotensin II (All) in plasma or the pulmonary circulation and do not block the conversion of native AI. Similarly, the C-terminal sequence of All is important for binding to receptor sites (6) . All analogues containing He in position 8 are potent competitive antagonists of All (7) . An AI analogue containing lie in position 8 might then interfere with the renin-angiotensin system by two mechanisms: (1) competing with AI for converting enzyme and (2) generating an All antagonist. In earlier pharmacologic studies (8, 9) , the decapeptide 8-Ile-AI was found to be weakly antagonistic to both AI and All in a variety of smooth muscle preparations and in the intact rat. Addition of the converting enzyme inhibitor SQ 20881 (Pyr-TrpPro-Arg-Pro-Gln-Ile-Pro-Pro) diminished but did not abolish the antagonism of 8-Ile-AI for All in the rat pressor assay, suggesting that conversion of small amounts of 8-Ile-AI to 8-Ile-AII took place in this preparation (8) . To further evaluate 8-Ilesubstituted AI for susceptibility to converting enzyme and ability to block the conversion of native AI, l-d-Asp-8-Ile-AI was synthesized and studied in vitro in plasma and in vivo in the pulmonary circulation of the intact dog. Comparisons with known peptide inhibitors of converting enzyme were made.
Methods

PEPTIDE-SYNTHESIS
The pentapeptide blocker BPP 5a (Pyr-Lys-Trp-AlaPro), l-/-Asp-5-Ile-AI (henceforth called AI), l-dAsp-8-Ile-AI, and l-d-Asp-8-Ile-AII were synthesized manually by the solid-phase technique (10, 11) . The tbutyloxycarbonyl derivative of d-aspartic acid was prepared as a custom synthesis by Bachem, Inc.; the other amino acids used were obtained from Beckman. The subsequent steps in synthesis and purification of the four peptides were essentially the same as those described previously (1). Final yields of purified peptide were 30-35%. The nonapeptide blocker SQ 20881 (Pyr-Trp-19
Pro-Arg-Pro-Gln-Ile-Pro-Pro) was also used. Ile-AII, BPP 5a> and SQ 20881 were subjected to bioassay using an intact dog anesthetized with sodium pentobarbital. Test samples were paired with standards of known doses of AI and l-Z-Asp-5-Ile-AH (henceforth called All) (SchwarzMann Biochemical). Peptides were injected intravenously, and pressure was measured with a Statham strain gauge attached to a large-bore catheter in the abdominal aorta.
IODINATION PROCEDURE
AI, All, l-f/-Asp-8-Ile-AI, and l-d-Asp-8-Ile-AII were labeled with 125 I by the chloramine-T method of Greenwood et al. (12) as modified by Nielsen et al. (13) . The details of the iodination procedure and the purification of the monoiodinated peptides on columns of DEAE Sephadex A-25 have been described previously (5) . Over 95% of the labeled material eluted from the columns was monoiodinated peptide. Estimated specific activity of the monoiodinated species was 700 mc//umole. The monoiodinated peptides were either used immediately or frozen with lysozyme (1 mg/ml) and stored at -20°C.
PREPARATION OF PEPTIDE STANDARDS
To develop a system for distinguishing generated All and l-d-Asp-8-Ile-AII from AI, l-d-Asp-8-Ile-AI, and the products of other circulating enzymes, peptide standards were prepared. Monoiodinated AI and AH were incubated with trypsin, chymotrypsin, or leucine aminopeptidase, as previously reported (5) . Each reaction mixture was divided into samples and either frozen on acetone and Dry Ice and stored at -20°C or spotted on Whatman 3MM paper and subjected to electrophoresis at 4,000 v for 1 hour in pyridine acetate buffer at pH 3.55. The paper was dried, cut' into 1-cm strips, and counted in a gamma counter. The stored samples were thawed and passed through a 0.9 X 100-cm column of DEAE Sephadex A-25 which was developed by the technique described for purification of iodinated peptides. Figure 1 position on both electrophoresis and chromatography and presumably consisted of the 1-8 sequence. Since all of the conversion experiments were analyzed by both techniques, it was possible to distinguish All from many of the probable peptide metabolities of AI, All, l-dAsp-8-Ile-AI, and l-(/-Asp-8-Ile-AII. Products of partial aminopeptidase digestion and of simultaneous digestion by multiple enzymes were not accounted for in these experiments.
IN VITRO METABOLISM
Samples (10 ml) of blood were drawn from the antecubital veins of normotensive laboratory personnel into iced 10-ml glass tubes containing heparin (143 USP units). The blood was spun immediately at 4°C in a refrigerated centrifuge, and the plasma fraction was removed. Each 1-ml sample of plasma was diluted (1:3.5) with O.lM Tris acetate buffer at pH 7.4 that contained O.lM NaCl (14) . To 1.5 ml of diluted plasma was added 1. 5 counts/min ml'HO.l pmole/ml) of diluted plasma. The mixture was incubated at 37°C, and samples (250 /xliters) were removed at frequent intervals; 50 /aliters of each sample was immediately spotted on Whatman 3MM paper and subjected to electrophoresis. The remaining 200 /^liters from each sample was treated with 3.4 mM 8-OH-quinoline (final concentration) and frozen. Each sample was passed through a column of DEAE Sephadex A-25, as previously described. Products were identified by comparison with standard peptides.
IN VIVO METABOLISM
Fifteen mongrel dogs of both sexes weighing 20-30 kg were anesthetized with sodium pentobarbital (20 mg/kg, iv), received a tracheostomy, and were placed on a Harvard respirator. Each dog was given heparin (1,000 units/kg, iv). A Swan-Ganz catheter was advanced into the pulmonary artery, as verified by the contour of the pressure tracing, and then withdrawn until a typical right ventricular pressure tracing was obtained. The catheter was left in the right ventricle for the remainder of the experiment. Large-bore retrograde catheters were placed in the ascending aorta and the abdominal aorta. Blood pressure was continuously monitored from the catheter in the abdominal aorta by a Statham pressure transducer and recorded on a photographicrecorder (Electronics for Medicine).
125 I-AI,
(1 x 10 8 counts/ min or 100 pmoles) was injected as a single bolus into the right ventricle of five dogs. This dose gave a concentration of circulating radioactive peptide in aortic plasma (1 X 10 5 counts/min ml" 1 or 0.1 pmole/ml) that approached physiological levels. In another set of experiments, SQ 20881, BPP 5a , or unlabeled l-d-Asp-8-Ile-AI (5 /nmoles) was injected as a bolus into the right ventricle, followed in 30 seconds by a second bolus (20 nmoles) of AI or AH. When a blunting of the pressor response appeared, the AI injection was repeated 5, 30, 60, 90, and 120 minutes after the administration of the blocker. Each blocker was administered to five dogs. Blood was collected in six sequential 10-ml samples from the ascending aorta at 5-second intervals. A series of plastic syringes connected via a manifold system and containing 2.6 mM ethylenediaminetetraacetate (EDTA), 1.6 mM dimercaptol, and 3.4 mM 8-OHquinoline (final concentration) was used for collection. Samples were processed and analyzed as previously described for plasma. The second and third sequential samples obtained 5-15 seconds after injection represented one circulation through the lung as determined by the appearance time of radioactive material. At least 30 minutes was allowed to elapse between injections to avoid interference with residual radioactive material.
Results
PEPTIDE CHARACTERIZATION
Amino acid analyses were performed on a Durrum analyzer after hydrolysis with 5.7N HCl for 24 hours at 110°C; Table 1 summarizes the results.
Acid hydrolysis yielded the amino acids in the ex- Each unlabeled peptide (1 mg) or each iodinated peptide (1 X 10 5 counts/min) was subjected to descending paper chromatography followed by electrophoresis in a second dimension as previously described (5) . Each peptide produced a single spot with ninhydrin-collidine stain or a single labeled spot.
To evaluate c/-Asp for racemization during synthesis, l-d-Asp-8-Ile-AI, AI, and l-d-Asp-8-Ile-AH were incubated with leucine aminopeptidase under conditions reported previously (5) , and the reaction mixtures were subjected to amino acid analysis. The AI digestion produced Asp in molar quantities equal to the quantity of peptide incubated. The l-d-Asp-8-Ile-AI and l-d-Asp-8-Ile-AII digestions produced no detectable free amino acids, indicating that there was no measurable lã spartic acid at the amino terminus. The l-rf-Asp-8-Ile-AI was evaluated for susceptibility to cleavage at the carboxyl terminus by incubation with carboxypeptidase A (diisopropyl fluorophosphate [DFP] treated). Two /^moles of peptide were allowed to react with 4.6 mg (2.5 units) of carboxypeptidase A in 2 ml of 0.1M NH 4 HCO 3> pH 7.9 at 37°C for 5 minutes. Amino acid analysis of the reaction mixture showed He, His, and Leu in molar quantities equal to the quantity of pcptide incubated.
HIGH VOLTAGE PAPER ELECTROPHORESIS
BIOASSAY
In dogs anesthetized with sodium pentobarbital, the pentapeptide (BPP 5a ) and the nonapeptide (SQ 20881) inhibitors in doses up to 1 mg/kg had no effect on resting blood pressure. A 5-/xmole dose of l-d-Asp-8-Ile-AI or l-d-Asp-8-Ile-AII caused a rise in mean blood pressure of 10 ± 3 mm Hg; a 20-nmole dose of AI or All caused a rise in mean blood pressure of 36 ± 5 mm Hg. Thus, the Table 2 . The nonapeptide inhibitor blocked conversion so that no All appeared; AI was eventually degraded by plasma angiotensinases. The pentapeptide and l-d-Asp-8-Ile-AI delayed conversion so that the half-time for disappearance of AI was 10 minutes, and the total All generated was less than that generated in uninhibited plasma. The l-d-Asp-8-Ile-AI was stable in plasma at 37°C; after 60 minutes, no conversion was observed and only 5% degradation was seen.
IN VIVO METABOLISM
Typical blood pressure responses to injection of AI or inhibitor followed by injection of AI are shown in Figure 3 . AI alone produced a mean 
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systolic pressor response of 44 ± 5 (SE) mm Hg and a mean diastolic pressor response of 32 ± 3 mm Hg within 30 seconds after injection. Treatment with the nonapeptide inhibitor abolished the pressor response to AI but did not lower base-line blood pressure. Responsiveness to the pressor effects of AI gradually returned to normal over a 90-minute period. After treatment with the pentapeptide inhibitor, the mean increase in systolic pressure was 38 ± 4 mm Hg, and the mean increase in diastolic pressure was 28 ± 6 mm Hg. Both values were unchanged compared with the results of an injection of a similar dose of AI alone. Following injection of l-d-Asp-8-Ile-AI, the mean pressor response to AI was increased to 57 ± 8/45 ± 4 mm Hg, probably because of the agonistic effect of the blocker. None of the inhibitors of the converting enzyme altered the pressor response to exogenous All. Figure 4 summarizes the results of a representative experiment using 125 I-labeled peptides. Following injection of 125 I-AI alone, 58% of the radioactive material appearing in the pulmonary HIGH VOLTAGE PAPER ELECTROPHORESIS DEAE SEPHADEX I-AI was injected in subpressor doses and was circulating in concentrations (0.1 pmole or 100 pg/ml) that approached physiological levels. Furthermore, l-cZ-Asp-8-Ile-AI injected into the pulmonary circulation in 250-fold molar excess (250 nmole/kg) did not cause a diminution of the pressor response to AI administered 0.5-5 minutes later. Larger doses of l-f/-Asp-8-Ile-AI were not evaluated because of its intrinsic pressor activity. Rapid inactivation of l-c/-Asp-8-Ile-AI was not a factor; the peptide was more stable than AI in plasma and in the pulmonary circulation, presumably because of protection from plasma aminopeptidases conferred by the d-Asp substitution in position 1 (15) .
In equimolar concentrations, the pentapeptide inhibitor BPP 5a behaved similarly to l-d-Asp-8-Ile-AI, and the nonapeptide inhibitor SQ 20881 completely blocked both the conversion of 125 I-AI to 125 I-AII and the pressor response to AI. The block lasted for 60-90 minutes in vivo. The Bothrops jararaca peptide BPP 5a has been reported to have a potent inhibitory effect on partially purified converting enzyme from rabbit lung in vitro (16) but a weak, transitory effect on conversion in vivo (16, 17) , requiring constant infusion of large doses to produce an effect. The small magnitude of the in vivo effect of BPP-could be due to its rapid removal from the circulation by proCirculatum Research, VoL XXXIV, January 1974
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teolytic enzymes or peripheral vascular beds or to its capacity to serve as an alternate substrate for converting enzyme (16, 17) . In contrast, the nonapeptide inhibitor SQ 20881 is a potent competitive inhibitor of converting enzyme both in vitro and in vivo (16) . It has a protracted inhibitory effect on the pressor response to exogenous or endogenous AI in a number of species (18) (19) (20) . In our study, failure of l-d-Asp-8-Ile-AI and BPP 5a to block conversion when given by the same route and in molar amounts equal to an effective blocking dose of SQ 20881 contradicts the possibility that converting enzyme excess is an explanation for the ineffectiveness of the first two inhibitors.
The l-d-Asp-8-Ile-AI was a poor substrate for Al-converting enzyme; this finding is evidenced by This finding is compatible with the recent demonstration that the affinities of both inhibitors and substrates for a common binding site on purified converting enzyme from rabbit lung are increased when an aromatic residue is in the third position from the C-terminus (position 8 of AI) (22).
The current study extends previous observations about the importance of the C-terminal sequence of AI for the specificity of Al-converting enzyme in vivo and in vitro (5) . In the earlier study, AI analogues containing d-amino acid substitutions, in positions 10 and 8 were not susceptible to conversion and did not block conversion of native AI; AI analogues containing r/-aminoacid substitutions in positions 7 and 5 were susceptible to conversion, although at a slower rate than AI, but they did not block the conversion of AI. All of these findings are consistent with the observations that the C-terminal tripeptide portions of inhibitors compete with the C-terminal portions of substrate at the active site of purified pulmonary converting enzyme and that the affinity of inhibitors for converting enzyme is affected by binding to a second site farther from the C-terminus (22).
